Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aptose Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
APTO
Nasdaq
8731
https://aptose.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aptose Biosciences Inc
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript
- Mar 27th, 2024 12:26 pm
Aptose Reports Results for the Fourth Quarter and Full Year 2023
- Mar 26th, 2024 8:01 pm
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
- Mar 18th, 2024 8:30 pm
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
- Feb 5th, 2024 3:24 pm
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
- Jan 31st, 2024 9:01 pm
This Aptose Biosciences Insider Increased Their Holding In The Last Year
- Jan 29th, 2024 1:32 pm
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
- Jan 26th, 2024 1:00 pm
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
- Dec 9th, 2023 11:30 pm
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
- Nov 30th, 2023 9:59 pm
Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript
- Nov 10th, 2023 4:21 pm
Aptose Reports Results for the Third Quarter 2023
- Nov 9th, 2023 9:00 pm
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
- Nov 2nd, 2023 1:00 pm
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
- Oct 30th, 2023 1:15 pm
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
- Oct 26th, 2023 11:11 am
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
- Oct 23rd, 2023 11:30 am
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
- Oct 16th, 2023 11:30 am
Aptose to Present at the Cantor Global Healthcare Conference
- Sep 18th, 2023 11:45 am
Companies Like Aptose Biosciences (TSE:APS) Could Be Quite Risky
- Sep 8th, 2023 6:36 pm
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
- Sep 6th, 2023 11:45 am
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Aug 24th, 2023 11:30 am
Scroll